### INN
Vincristine

### ATC codes
L01CA02

### Medicine type
Chemical agent

### EML status history
- First added in 1977 (TRS 615) for Unspecified malignant neoplasms of ill-defined or unspecified sites
- Added in 2011 (TRS 965) for Burkitt lymphoma including Burkitt leukaemia
- Added in 2011 (TRS 965) for Malignant neoplasms of kidney, except renal pelvis
- Added in 2011 (TRS 965) for Lymphoid leukaemia, not elsewhere classified
- Added in 2015 (TRS 994) for Rhabdomyosarcoma primary site
- Added in 2015 (TRS 994) for Retinoblastoma
- Added in 2015 (TRS 994) for Hodgkin lymphoma
- Added in 2015 (TRS 994) for Follicular lymphoma
- Added in 2015 (TRS 994) for Malignant trophoblastic neoplasms of placenta
- Added in 2015 (TRS 994) for Diffuse large B-cell lymphomas
- Added in 2015 (TRS 994) for Kaposi sarcoma of other specified primary sites
- Added in 2015 (TRS 994) for Ewing sarcoma of bone and articular cartilage of unspecified sites
- Removed in 2015 (TRS 994) for Unspecified malignant neoplasms of ill-defined or unspecified sites

### Wikipedia
Vincristine

### DrugBank
Vincristine
Cytotoxic medicines

Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)

Indications

- Rhabdomyosarcoma primary site
- Diffuse large B-cell lymphomas
- Malignant trophoblastic neoplasms of placenta
- Hodgkin lymphoma
- Kaposi sarcoma of other specified primary sites
- Follicular lymphoma
- Retinoblastoma
- Ewing sarcoma of bone and articular cartilage of unspecified sites
- Malignant neoplasms of kidney, except renal pelvis
- Lymphoid leukaemia, not elsewhere classified
- Burkitt lymphoma including Burkitt leukaemia
- Unspecified malignant neoplasms of ill-defined or unspecified sites